FDA's April 30, 2026 Proposal On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances when FDA-approved versions are available
Our weight loss specialists review your medical history, goals, and preferences to help determine which medication may work best for you
Tirzepatide is a groundbreaking medication that was originally developed for the treatment of type 2 diabetes
I should have been on it yesterday.' But without FDA oversight, Dr
How to find out what you are taking Contact your pharmacy and ask two specific questions
Maintenance dosing and long-term plans Once you reach your goal weight, the question becomes whether to continue tirzepatide and at what dose